Shares of Simulations Plus, Inc. (NASDAQ:SLP – Get Free Report) have been assigned an average rating of “Reduce” from the eight research firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating and seven have given a hold rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $17.25.
A number of research analysts have recently weighed in on the stock. William Blair downgraded shares of Simulations Plus from an “outperform” rating to a “market perform” rating in a report on Wednesday, June 17th. Craig Hallum cut shares of Simulations Plus from a “buy” rating to a “hold” rating and set a $18.50 price objective for the company. in a report on Thursday, June 18th. Wall Street Zen downgraded shares of Simulations Plus from a “buy” rating to a “hold” rating in a research report on Saturday, June 13th. Finally, Weiss Ratings raised Simulations Plus from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, July 10th.
Get Our Latest Stock Analysis on SLP
Simulations Plus Stock Performance
Simulations Plus (NASDAQ:SLP – Get Free Report) last issued its quarterly earnings data on Thursday, July 9th. The technology company reported $0.30 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.07. The firm had revenue of $21.89 million for the quarter, compared to analyst estimates of $20.90 million. Simulations Plus had a net margin of 9.88% and a return on equity of 13.50%.
Insider Buying and Selling at Simulations Plus
In related news, Director Walter Woltosz sold 4,177 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $18.44, for a total value of $77,023.88. Following the completion of the sale, the director directly owned 3,202,131 shares in the company, valued at approximately $59,047,295.64. The trade was a 0.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 19.10% of the company’s stock.
Hedge Funds Weigh In On Simulations Plus
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new stake in shares of Simulations Plus during the 2nd quarter worth $27,503,000. First Light Asset Management LLC lifted its position in Simulations Plus by 33.7% during the 1st quarter. First Light Asset Management LLC now owns 2,632,823 shares of the technology company’s stock worth $31,120,000 after acquiring an additional 663,906 shares during the last quarter. Meros Investment Management LP acquired a new position in Simulations Plus during the 4th quarter worth $6,184,000. Glazer Capital LLC bought a new stake in Simulations Plus during the second quarter valued at about $3,691,000. Finally, Renaissance Technologies LLC boosted its holdings in Simulations Plus by 807.5% during the first quarter. Renaissance Technologies LLC now owns 181,500 shares of the technology company’s stock valued at $2,145,000 after acquiring an additional 161,500 shares during the period. Institutional investors and hedge funds own 78.08% of the company’s stock.
About Simulations Plus
Simulations Plus, Inc develops software and provides consulting services for pharmaceutical and biotechnology companies involved in drug discovery and development. Its modeling and simulation tools are designed to help researchers evaluate drug candidates, understand how medicines move through the body, assess safety risks and support decisions throughout the development process.
The company’s products include GastroPlus, a platform used for physiologically based pharmacokinetic and biopharmaceutic modeling; ADMET Predictor, which helps predict absorption, distribution, metabolism, excretion and toxicity characteristics; and DILIsym, a software platform focused on drug-induced liver injury.
Read More
- Five stocks we like better than Simulations Plus
- Data Centers Got the AI Hype—But Office REITs May Get the Rent Hikes
- 2 Cybersecurity Stocks Breaking Out as AI Continues to Be a Tailwind
- 3 More AI Infrastructure Plays Beyond the Big Names
- CAVA Stock Slips: Sector Fear or Valuation Reality?
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.
